Diabetes care Exam: Quiz!

Reviewed by Editorial Team
The ProProfs editorial team is comprised of experienced subject matter experts. They've collectively created over 10,000 quizzes and lessons, serving over 100 million users. Our team includes in-house content moderators and subject matter experts, as well as a global network of rigorously trained contributors. All adhere to our comprehensive editorial guidelines, ensuring the delivery of high-quality content.
Learn about Our Editorial Process
| By DR GOPALA
D
DR GOPALA
Community Contributor
Quizzes Created: 1 | Total Attempts: 396
| Attempts: 396
SettingsSettings
Please wait...
  • 1/20 Questions

    A 50-year-old man with a history of myocardial infarction has new-onset type 2 diabetes with HbA1C 8%. You are considering drug treatment, the first drug to be considered is

    • Metformin
    • Gliptins
    • SGLT2 inhibitor
    • GLP-1 agonists
Please wait...
About This Quiz

The 'Diabetes Care Exam: Quiz!' assesses knowledge on diabetes management, focusing on microvascular risks, cardiovascular events, and appropriate HbA1C goals. It includes questions on ADA guidelines and medication choices, essential for healthcare professionals and students in medicine.

Diabetes care Exam: Quiz! - Quiz

Quiz Preview

  • 2. 

    According to ADA guidelines diagnostic criteria for diabetes by HbA1C

    • Diabetes is diagnosed if HbA1c ≥ 6% in at least 2 measurements

    • Diabetes is diagnosed if HbA1c ≥ 6.5% in at least 2 measurements

    • Diabetes is diagnosed if HbA1c ≥ 7% in at least 2 measurements

    • Diabetes is diagnosed if HbA1c ≥ 7.5% in at least 2 measurements

    Correct Answer
    A. Diabetes is diagnosed if HbA1c ≥ 6.5% in at least 2 measurements
    Explanation
    According to ADA guidelines, diabetes is diagnosed if HbA1c is greater than or equal to 6.5% in at least 2 measurements. This means that if a person's HbA1c level is consistently 6.5% or higher in multiple tests, they can be diagnosed with diabetes. This threshold is used to determine the presence of diabetes based on the average blood sugar levels over a period of time.

    Rate this question:

  • 3. 
    Multiple gas-containing cysts in the submucosal or subserosal layer of the intestine (Pneumatosis) It may be associated with a range of GI conditions such as bowel gangrene to inflammatory bowel disease and rarely with mechanical ventilation and endoscopic procedures. Which antidiabetic drug is associated with this rare condition? - ProProfs

    Multiple gas-containing cysts in the submucosal or subserosal layer of the intestine (Pneumatosis) It may be associated with a range of GI conditions such as bowel gangrene to inflammatory bowel disease and rarely with mechanical ventilation and endoscopic procedures. Which antidiabetic drug is associated with this rare condition?

    • Rosiglitazone

    • Dapagliflozin

    • Saxagliptin

    • Acarbose

    Correct Answer
    A. Acarbose
    Explanation
    Acarbose is an antidiabetic drug that is associated with the rare condition of multiple gas-containing cysts in the submucosal or subserosal layer of the intestine, known as pneumatosis. This condition can be linked to various gastrointestinal conditions such as bowel gangrene and inflammatory bowel disease. While mechanical ventilation and endoscopic procedures can also be causes, in this case, the association is with the use of Acarbose as an antidiabetic medication.

    Rate this question:

  • 4. 

    The following drugs are not to be used in T2D patients with CHF.

    • GLP1 agonists and SGLT2i

    • α-glucosidase inhibitors and Linagliptin

    • Linagliptin and Dapagliflozin

    • TZDs and Saxagliptin

    Correct Answer
    A. TZDs and Saxagliptin
    Explanation
    TZDs (thiazolidinediones) and Saxagliptin should not be used in patients with type 2 diabetes (T2D) and congestive heart failure (CHF). This is because TZDs can cause fluid retention and exacerbate CHF symptoms, while Saxagliptin has been associated with an increased risk of heart failure in some studies. Therefore, it is important to avoid these drugs in T2D patients with CHF to prevent worsening of their heart condition.

    Rate this question:

  • 5. 

    The following class of drugs acts by stimulating the pancreas to produce more insulin.

    • Sulfonylureas

    • Meglitinides

    • Gliptins

    • A and b

    • A and c

    Correct Answer
    A. A and b
    Explanation
    Sulfonylureas and meglitinides are classes of drugs that stimulate the pancreas to produce more insulin. Sulfonylureas work by closing potassium channels in the beta cells of the pancreas, which causes an increase in insulin release. Meglitinides also stimulate insulin release by binding to the ATP-sensitive potassium channels in the beta cells. Therefore, both a and b are correct answers as they represent classes of drugs that stimulate the pancreas to produce more insulin.

    Rate this question:

  • 6. 

    The following oral hypoglycemic agent raised serious concern about cardiovascular safety resulting in FDA guidance to industry to evaluate CV risk in new therapies to treat T2D in 2008.

    • Saxagliptin

    • Rosiglitazone

    • Repaglinide

    • Exenatide

    Correct Answer
    A. Rosiglitazone
    Explanation
    Rosiglitazone is the correct answer because it raised serious concerns about cardiovascular safety, leading the FDA to issue guidance to evaluate cardiovascular risk in new therapies for treating type 2 diabetes in 2008. This indicates that there were significant issues with the cardiovascular safety profile of rosiglitazone, prompting regulatory action to ensure the evaluation of cardiovascular risks in similar medications.

    Rate this question:

  • 7. 

    Which of the following drugs can be used in patients with CKD (eGFR < 30ml/min)

    • Metformin

    • Glibenclamide

    • Linagliptin

    • Empagliflozin

    Correct Answer
    A. Linagliptin
    Explanation
    Linagliptin can be used in patients with CKD (eGFR < 30ml/min) because it is primarily excreted through the feces, rather than the kidneys. This means that it does not accumulate in the body and does not require dose adjustment in patients with renal impairment. Metformin, Glibenclamide, and Empagliflozin, on the other hand, are not recommended in patients with CKD due to the risk of adverse effects and potential accumulation in the body.

    Rate this question:

  • 8. 

    Testing for diabetes in asymptomatic individuals should be considered in overweight or obese who have one or more of the following risk factors except:

    • First-degree relative with diabetes

    • Hypertension (≥140/90 mmHg or therapy for hypertension)

    • Active smoker

    • Women with polycystic ovary syndrome

    Correct Answer
    A. Active smoker
    Explanation
    Testing for diabetes in asymptomatic individuals should be considered in overweight or obese individuals who have one or more of the following risk factors: first-degree relative with diabetes, hypertension (≥140/90 mmHg or therapy for hypertension), or women with polycystic ovary syndrome. Being an active smoker is not considered a risk factor for diabetes in this context, therefore, testing for diabetes is not recommended for active smokers who are overweight or obese.

    Rate this question:

  • 9. 

    According to ADA all of the following are the criteria for the diagnosis of diabetes except

    • FPG ≥ 110 mg/dL

    • HbA1C ≥ 6.5%

    • 2-h PG ≥ 200 mg/dL

    • Classical symptoms of hyperglycemia and random PG ≥ 200 mg/dL

    Correct Answer
    A. FPG ≥ 110 mg/dL
    Explanation
    The American Diabetes Association (ADA) has established criteria for the diagnosis of diabetes, which includes elevated levels of fasting plasma glucose (FPG) of 110 mg/dL or higher, HbA1C levels of 6.5% or higher, and 2-hour plasma glucose (PG) levels of 200 mg/dL or higher. Additionally, the presence of classical symptoms of hyperglycemia and random PG levels of 200 mg/dL or higher can also be used for diagnosis. However, FPG levels of 110 mg/dL or higher are not one of the criteria for the diagnosis of diabetes according to ADA.

    Rate this question:

  • 10. 

    One of the following drugs has shown benefit in cardiovascular outcomes in CHF in patients with and without T2DM?

    • Liraglutide

    • Empagliflozin

    • Metformin

    • Dapagliflozin

    Correct Answer
    A. Dapagliflozin
    Explanation
    Dapagliflozin has shown benefit in cardiovascular outcomes in patients with and without type 2 diabetes mellitus (T2DM) who have congestive heart failure (CHF). This drug belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by inhibiting the reabsorption of glucose in the kidneys and promoting its excretion in the urine. In clinical trials, dapagliflozin has been shown to reduce the risk of cardiovascular events, including heart failure hospitalization and cardiovascular death, in patients with CHF, both with and without T2DM.

    Rate this question:

  • 11. 

    Which of the following drugs has shown significant cardiovascular benefit in T2D with high CVD risk?

    • Empagliflozin

    • Dapagliflozin

    • Sitagliptin

    • Insulin

    Correct Answer
    A. Dapagliflozin
    Explanation
    Dapagliflozin has shown significant cardiovascular benefit in patients with type 2 diabetes (T2D) who have a high risk of cardiovascular disease (CVD). This drug belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by reducing blood sugar levels through the elimination of excess glucose in the urine. In addition to its glucose-lowering effects, dapagliflozin has been shown to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death, in patients with T2D and high CVD risk.

    Rate this question:

  • 12. 

    Fournier’s gangrene (acute perineal necrotizing fasciitis) is a serious complication of drug treatment of T2D. Which drug/drug class has been associated with this complication?

    • Saxagliptin

    • SGLT2i

    • GLP-1 agonists

    • Rosiglitazone

    Correct Answer
    A. SGLT2i
    Explanation
    SGLT2i, or sodium-glucose co-transporter 2 inhibitors, have been associated with Fournier's gangrene, a serious complication of drug treatment for type 2 diabetes. This class of drugs works by inhibiting the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. However, SGLT2 inhibitors have been linked to an increased risk of genital and urinary tract infections, which can potentially progress to Fournier's gangrene. Therefore, SGLT2 inhibitors should be used with caution in patients with risk factors for this complication.

    Rate this question:

  • 13. 

    Hypoglycemia is more common with the following drug/drugs.

    • Dapagliflozin

    • Linagliptin

    • Glimepride

    • 2&3

    • All of the above

    Correct Answer
    A. Glimepride
    Explanation
    Hypoglycemia is more common with Glimepride compared to the other drugs listed (Dapagliflozin and Linagliptin). This means that Glimepride has a higher likelihood of causing low blood sugar levels in patients.

    Rate this question:

  • 14. 

    The United Kingdom Prospective Diabetes Study (UKPDS) showed that intensive therapy (mean A1C value of 7%) with OHAs of insulin resulted in a decreased risk of microvascular complications compared with conventional therapy with diet (mean A1C value of 7.9%) at the end of the study 1997. According to UKPDS 0.9% reduction in A1C at 10 years was associated with a ___ reduction in microvascular endpoints.

    • 5%

    • 15%

    • 25%

    • 35%

    Correct Answer
    A. 25%
    Explanation
    The UKPDS study found that a 0.9% reduction in A1C levels at 10 years was associated with a 25% reduction in microvascular endpoints. This means that for every 0.9% decrease in A1C levels, there was a 25% decrease in the risk of developing microvascular complications such as retinopathy, nephropathy, and neuropathy. This highlights the importance of intensive therapy and maintaining good glycemic control in reducing the risk of these complications in patients with diabetes.

    Rate this question:

  • 15. 

    According to East-West Study:

    • Patients with DM but no CHD experience a higher rate of MI as patients without DM but with CHD

    • Patients with DM but no CHD experience a lower rate of MI as patients without DM but with CHD

    • Patients with DM but no CHD experience a similar rate of MI as patients without DM but with CHD

    Correct Answer
    A. Patients with DM but no CHD experience a similar rate of MI as patients without DM but with CHD
    Explanation
    The given answer suggests that patients with diabetes mellitus (DM) but no coronary heart disease (CHD) have a similar rate of myocardial infarction (MI) compared to patients without DM but with CHD. This implies that having DM alone does not significantly increase the risk of MI compared to having CHD alone. It suggests that the presence of DM without CHD does not independently contribute to a higher rate of MI.

    Rate this question:

  • 16. 

    The following drugs have shown cardiovascular benefits by decreasing MACE

    • Metformin and insulin

    • DPP4 inhibitors and Metformin

    • SGLT2 inhibitors and GLP-1 agonists

    • SGLT2 inhibitors and long acting GLP-1 agonists

    Correct Answer
    A. SGLT2 inhibitors and long acting GLP-1 agonists
    Explanation
    SGLT2 inhibitors and long-acting GLP-1 agonists have shown cardiovascular benefits by decreasing MACE (major adverse cardiovascular events). These drugs work by different mechanisms to improve cardiovascular outcomes. SGLT2 inhibitors reduce cardiovascular events by improving glycemic control, reducing blood pressure, and promoting weight loss. Long-acting GLP-1 agonists, on the other hand, improve cardiovascular outcomes by reducing cardiovascular risk factors, such as blood pressure and body weight, and by exerting direct protective effects on the heart. Therefore, the combination of SGLT2 inhibitors and long-acting GLP-1 agonists has been shown to be effective in reducing MACE.

    Rate this question:

  • 17. 

    In elderly long-standing diabetes with comorbidities the HBA1C goal is

    • 6-6.5%

    • 6.5-7%

    • 7-7.5%

    • 7.5-8%

    Correct Answer
    A. 7.5-8%
    Explanation
    In elderly individuals with long-standing diabetes and comorbidities, the recommended HBA1C goal is 7.5-8%. This range is slightly higher compared to the goals for younger individuals with diabetes. The higher goal is set to avoid the risk of hypoglycemia, which can be more dangerous in older adults. Additionally, elderly individuals may have other health conditions that need to be managed, and a slightly higher HBA1C goal allows for a more flexible and individualized approach to diabetes management.

    Rate this question:

  • 18. 

    According to ADA guidelines, the following combination of drugs is not recommended in the treatment of T2D.

    • DPP-4 inhibitors and GLP-1 agonists

    • GLP-1 agonists and SGLT2 inhibitors

    • SGLT2 inhibitors and TZDs

    • DPP-4 inhibitors and TZDs

    Correct Answer
    A. DPP-4 inhibitors and GLP-1 agonists
    Explanation
    According to ADA guidelines, DPP-4 inhibitors and GLP-1 agonists are not recommended in the treatment of T2D. This is because both of these drugs work by increasing the levels of GLP-1, which can lead to an increased risk of hypoglycemia and gastrointestinal side effects. Additionally, there is limited evidence on the safety and efficacy of combining these two drugs. Therefore, it is advisable to avoid this combination in the treatment of T2D.

    Rate this question:

  • 19. 

    Which of the following drug/drugs on long term treatment requires least number of patients to prevent one CV death (NNT) in T2D?

    • Statins

    • Antihypertensives

    • Aspirin

    • Empagliflozin

    • Liraglutide

    Correct Answer
    A. Empagliflozin
    Explanation
    Empagliflozin is the drug that requires the least number of patients to prevent one CV (cardiovascular) death in patients with type 2 diabetes (T2D). This is based on clinical studies and evidence that have shown the effectiveness of empagliflozin in reducing cardiovascular events and mortality in T2D patients. Therefore, compared to statins, antihypertensives, aspirin, and liraglutide, empagliflozin has the lowest NNT (number needed to treat) to prevent one CV death in T2D.

    Rate this question:

  • 20. 

    According to a meta-analysis of intensive glucose-lowering trials, the benefit of different interventions with 5-year treatment, which of the following results in better reduction of CV events?

    • Reduction of systolic BP (4 mmHg)

    • Reduction of HbA1C (0.9%)

    • Reduction of LDL cholesterol (38.6 mg/dL)

    • All of the above

    Correct Answer
    A. Reduction of systolic BP (4 mmHg)
    Explanation
    The meta-analysis of intensive glucose-lowering trials found that a reduction of systolic BP (4 mmHg) resulted in a better reduction of cardiovascular (CV) events. This means that lowering blood pressure by 4 mmHg had a greater impact on reducing CV events compared to reducing HbA1C levels by 0.9% or reducing LDL cholesterol by 38.6 mg/dL. Lowering blood pressure is an important intervention for preventing CV events and should be prioritized in treatment strategies.

    Rate this question:

Quiz Review Timeline (Updated): Mar 21, 2023 +

Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.

  • Current Version
  • Mar 21, 2023
    Quiz Edited by
    ProProfs Editorial Team
  • Sep 27, 2019
    Quiz Created by
    DR GOPALA

Recent Quizzes

DIABETES CARE - HRUDOY 2019 DIABETES CARE - HRUDOY 2019
Managing Your Diabetes 8 Videos Managing Your Diabetes 8 Videos
Glucose and carbohydrates quiz Glucose and carbohydrates quiz
Diabetes Module Post Test Diabetes Module Post Test
SCUSD Diabetes eTraining Quiz SCUSD Diabetes eTraining Quiz
Integrated Chronic Care Management for Diabetes: Post-Test Integrated Chronic Care Management for Diabetes: Post-Test
Back to Top Back to top
Advertisement
×

Wait!
Here's an interesting quiz for you.

We have other quizzes matching your interest.